Article
When to Test: A Provider's Guide to TruDiagnostic Testing Timing and Cadence
Methylation is more stable than routine labs — but illness, surgery, and pregnancy can still skew a result. A quick-reference guide to when to test, wait, or retest.
When to Test: A Provider's Guide to TruDiagnostic Testing Timing and Cadence
One of the most common questions providers ask after ordering their first TruDiagnostic test isn't about interpretation — it's about timing. When should patients test? When should they wait? How often should they retest?
These are practical questions, and the answers matter. Methylation patterns are far more stable than conventional labs — they aren't swayed by routine day-to-day fluctuations the way markers like CRP or cortisol are. But significant physiological stress, such as a major illness, surgery, or pregnancy, can still transiently shift specific results. Testing during one of these windows won't produce an inaccurate result, but it may produce one that doesn't represent a patient's stable biological baseline — making it harder to interpret and harder to use as a benchmark for future comparison.
Quick reference: common testing scenarios
| Scenario | Recommendation | Rationale |
|---|---|---|
| Healthy patient, no active interventions | Quarterly (4x/year) | Captures seasonal and longitudinal trends |
| Tracking a specific intervention | Baseline before → retest at 3–6 months | Allows time for methylation patterns to shift |
| Recent acute illness (cold, flu, respiratory) | Wait 4–6 weeks after full recovery | Systemic inflammation can transiently affect methylation signals |
| Post-surgery (major) | Wait 8–12 weeks | Surgical stress, anesthesia, and recovery cause significant disruption |
| Pregnancy | Testing is possible, but more difficult to interpret during active pregnancy | Methylation shifts substantially and falls outside standard reference data, so results can't be reliably interpreted |
| GLP-1 agonists (semaglutide, tirzepatide) and other targeted interventions | Test before starting → retest at 3–6 months | Capture biological baseline and measure intervention effect |
Why timing matters for methylation testing
Methylation is a far more stable signal than most conventional labs — it reflects cumulative biology rather than moment-to-moment fluctuation, which is part of why it's useful for tracking aging and health trends over time rather than day-to-day noise. But it isn't entirely immune to major physiological disruption. Significant events — a serious illness, major surgery, pregnancy — can shift methylation patterns enough to obscure a patient's stable baseline, even though routine day-to-day variation won't.
The goal of good testing timing is to capture a reading that represents that stable baseline — not a transient state caused by an unusual physiological event. This is especially important for establishing a baseline. If a patient's first test is taken three weeks after a major illness, their results may normalize significantly on retest a few months later — making it difficult to know what the true intervention effect was versus recovery.
Acute illness
Systemic illness — particularly anything with fever, significant inflammation, or immune activation — can transiently alter methylation patterns. Wait four to six weeks after full clinical recovery before testing. This applies to flu, COVID-19, and other acute inflammatory events. Minor colds without significant systemic symptoms are generally less concerning, but when in doubt, waiting is the lower-risk choice.
Surgery
Major surgery is one of the most significant physiological stressors a body can experience. Anesthesia, surgical trauma, the inflammatory cascade of recovery, and post-operative medications all create a biological environment that isn't representative of a patient's stable state. Wait eight to twelve weeks after major surgery before testing. Minor outpatient procedures with minimal systemic impact carry less concern, but the same principle applies: test when the patient is back to baseline function.
Pregnancy
Methylation patterns shift dramatically during pregnancy as part of normal hormonal regulation and fetal programming. These shifts are expected, but they mean results during pregnancy fall outside the reference data used to interpret TruDiagnostic results. Testing can still be done during pregnancy — there's no clinical reason to avoid it — but the results will be more challenging to interpret: they'll reflect pregnancy-related methylation changes that can influence age metrics or health status, with no reference population to benchmark against. We recommend waiting until after delivery to establish a baseline; most providers wait approximately three months postpartum.
GLP-1 agonists and other interventions
GLP-1 receptor agonists (semaglutide, tirzepatide) are among the most important medications to consider in the context of methylation testing. Emerging data — including analysis from TruDiagnostic's own datasets — suggests these medications produce measurable changes in epigenetic aging markers, including slowing of DunedinPACE and improvements in metabolic EBPs.
Recommended approach: Test before initiating GLP-1 therapy to establish a clean baseline, then retest at three to six months. This gives providers and patients objective, methylation-level data on how the medication is affecting biological aging — beyond weight and metabolic markers.
For other medications with known epigenetic activity (metformin, corticosteroids, antiepileptics), the same logic applies: test before the change and after a stable period on the new regimen.
Supplements
B vitamins and other methyl donors (SAM-e, TMG) directly participate in the one-carbon metabolism pathway that drives methylation. Very high doses can, in theory, influence methylation patterns. Most patients on standard supplementation doses won't see a significant effect — but don't dramatically change a supplement regimen in the weeks immediately before testing, and wait at least three months after initiating a major supplement protocol before testing.
Testing cadence and strategy
For new patients without specific intervention goals: Start with a baseline test. This becomes the reference point for everything that follows. Retest quarterly to track trends over time.
For patients tracking an intervention: The most important test is the baseline — before the intervention begins. The second test should follow the intervention by at least three months, and ideally closer to six months, to allow methylation patterns enough time to shift. DunedinPACE will often show improvement first; overall biological age takes longer.